Back to results
US 2011/0217233 A1Published application
Modulation of intracellular signaling
AssigneeAngstrom Pharmaceuticals, Inc.
InventorsMalcolm Finlayson, Bassam B. Damaj
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAngstrom Pharmaceuticals, Inc.
InventorsMalcolm Finlayson, Bassam B. Damaj
Estimating the term…
A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.
A method of treating a disease characterized by aberrant cell migration and/or invasion comprising administering to a subject an effective amount of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease.
A method of diagnosing a condition characterized by aberrant cell migration and/or invasion comprising measuring the effect of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 on FAK signal transduction activity;
A method of diagnosing a condition characterized by aberrant cell migration and/or invasion comprising imaging the FAK signal transduction activity in the presence of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17.
Dependencies are inferred from the claim text.